Clinuvel

How long have you been invested in Clinuvel?

  • 0-1 Year

    Votes: 2 1.6%
  • 1-3

    Votes: 8 6.5%
  • 3-5

    Votes: 18 14.5%
  • 5-10

    Votes: 19 15.3%
  • 10-15

    Votes: 31 25.0%
  • 15-20

    Votes: 37 29.8%
  • 20+

    Votes: 9 7.3%

  • Total voters
    124
  • Poll closed .

Watene

Well-known member
One thing of note (perhaps) is that Shorty has not breached 4% in the past month.....hmmm.
Perhaps their ceiling of exposure is capped at 4%, therefore they may be limited in how much control they have over CUV.

Given they have pushed (sold) on the 8th, 11th and 12th to suppress the share price, then perhaps today they are too close to the 4% to sell lots today and suppress the price further? Hence up we go.
Just an observation...nothing more. Hope it is the case though :LOL:

1634177762740.png
 

frootloops

6th Longest Active Member
@Watene

@Watene. From a technical point of view i'll give you my take on what's happening here. We didn't breach the $45 level. Resistance. Fair enough. The markets then look to retrace & lets be fair.....we've had a bloody good run the past month. I use Fibonacci levels at times like this. It's amazing how accurate they can be. So where to from here. Next stop is the 38.2% Fib level which stands at 37.70. If that fails the 50% mark is 35.55. Those wanting to know below that is 61.8% at 33.39. I'm not advocating any figure. Watch & wait. But if you're keen 4 more shares those levels may help you.
 

Sherlock

Well-known member
Thanks all for the insights regarding my shorting comment. Besides the content I appreciate once again the collected knowledge and respect towards each other here. Thanks mods for setting it up! And yeah, that was another one of my stuck records which I don't mind playing over and over!
 

Toktok

Well-known member
It seems our short algos are also in for the long term...my personal take is that they are set up by humans for hedging larger positions and that is what they do. Most of it is automated and based on artificial intelligence algorithms.
It makes mostly no sense for us humans and they have no feelings so I don't bother too much. They will also do the bot dance at 100aud.

What fundamental news will be first?
-AIS update and readouts 6 patients
-numbers in the quarterlies
-strategy update

Or else:
-news from China
-vitiligo snippet from the fda
- a view on the manufacturing readiness

The expansion door is indeed wide open now for cuv but they did not get through it yet.
 

DenzelWash

Well-known member
The expansion door is indeed wide open now for cuv but they did not get through it yet.
And I think they are preparing everything for this next step. No Instagram posts over a month already…I start to believe the intention for this was never to raise awareness or reaching new investors…I think they are setting somehow of a company tracking history for future interests…the same with YouTube and all other SM appearance
 
Last edited:

FarmaZutical

Well-known member
@DenzelWash I’ve vented the same thoughts previously and a totally agree. The SoMe posts over the past years have been weird sometimes. Often, in fact. On the surface they have been preaching to the choir since no one is really paying attention and their following is smaller than the one of my local supermarket on Instagram. But the strategy might not be that silly after all, because when they hit the red button and launch the revolutionary products or enter a mega blockbuster indication (insert prayer to whatever God you believe in here), new investors and potential suitors will start digging to see if this strange Australian company is the real deal or a shell. All the scientific communiqués, the Some posts, and the strategic updates will serve a purpose here. I’d probably delete the “articles” by the infamous Giles Delaney, though.

So yeah, I agree. It seems like a real strategy. But only if they deliver the goods at some point, because otherwise it’s just strange.
 

investek

Well-known member
And suggestions of "Spill the Board" are completely disingenuous because it's mathematically impossible and those that say know it. Events have changed my opinion recently, and I believe management is right for the job.
Apologies for my ignorance but why do you say it’s mathematically impossible for Resolution 4 - Spill resolution, to be passed?

I agree that it is unlikely a spill resolution will be passed, esp. given the share price is back close to all time highs and resolution 1 (rem report) would have to be voted down to trigger a spill poll, let along the ~8mil+ votes probably needed to pass the resolution. However by my calculations it is not impossible (just highly improbable), what am I missing?

Also I make a distinction between ‘management’ as primarily leading operations and ‘the board’ as primarily a governance body. See below.
DC956A5A-2ABC-4D90-8E60-1DE33789EB02.jpeg

That is to say, that in my humble opinion, it is entirely possible to have faith and confidence with company management but take issue with aspects of the board/governance.

Furthermore, it is my understanding and please correct me if I’m mistaken, that if a spill resolution was passed it would simply mean directors (except the CEO) would be required to stand for re-election (within 90 days?) should the directors choose to do so.
 

macgyver

Well-known member
It seems our short algos are also in for the long term...my personal take is that they are set up by humans for hedging larger positions and that is what they do. Most of it is automated and based on artificial intelligence algorithms.
It makes mostly no sense for us humans and they have no feelings so I don't bother too much. They will also do the bot dance at 100aud.

What fundamental news will be first?
-AIS update and readouts 6 patients
-numbers in the quarterlies
-strategy update

Or else:
-news from China
-vitiligo snippet from the fda
- a view on the manufacturing readiness

The expansion door is indeed wide open now for cuv but they did not get through it yet.
Maybe a readout from the first XP patient. Surely they finished treatment by now:unsure:

I'm curious as to whether they will announce the 5/6th indication in the SU3. There has to be a significant inclusion or change in it, otherwise not much point calling it a strategic update. More like another operations update. PW said in the annual report they expect to begin work on the new indication in 2022 with it being a 'pivotal year'. Shouldn't be too far off having worked out the details with key stakeholders. A new indication announced tied with an appreciating share price over the last few weeks would be a timely boost for morale after a deflating 2021.
 
Last edited:

Frogster

Well-known member
@macgyver I'm wondering if SU3 will focus on the OTC programme, and maybe even include a near term launch schedule. They've been telling us for ages they are close to launching, and talking about that whole product class thrust is closer to a strategic topic than many other data points we can also hope for. For example, an AIS update would be great to have, but if we get one and if the data has been good, don't we then just get confirmation the next steps are to replicate the trial elsewhere as has been disclosed already? That'd be a tremendous step of course, but a different type of announcement in my book.

If SU3 is focused on OTCs with a launch programme, maybe the pause in SoMe updates has been planned to come back with a bang around these details.

Anyway, shouldn't be too long to wait till this speculation becomes moot.
 

macgyver

Well-known member
For example, an AIS update would be great to have, but if we get one and if the data has been good, don't we then just get confirmation the next steps are to replicate the trial elsewhere as has been disclosed already? That'd be a tremendous step of course, but a different type of announcement in my book.
Yes good point. And if we look at the recent key dates announcement it does say in the small print down the bottom:

ED054A77-5492-4689-A111-B114B4C42B8A.jpeg


So it appears clinical results will be declared separately. In SU2 they were more specific about the OTCs i.e the three target groups (were they mentioned in the first SU? I can’t remember), so it makes sense if they give more detail and expanded on the OTCs. Definitely view a new indication as a strategic play though as the indication will likely lead to treatment across several diseases within the field e.g. Alzheimer’s indicated leads to treating other CNS disorders.
 
Last edited:

CUV Quote (Yesterday's close)

Time: 4:10PM AEDT
Price: 28.10
Volume: 129698
Top